N※N

Dietary Supplement Industry Pushes for FDA Approval Overhaul

  //food-wine.news-articles.net/content/2026/03/28 .. t-industry-pushes-for-fda-approval-overhaul.html
  Published in Food and Wine on Saturday, March 28th 2026 at 15:13 GMT by abc7NY
      Locale: UNITED STATES

NEW YORK, NY - March 28th, 2026 - A major push is underway by dietary supplement manufacturers to overhaul the Food and Drug Administration's (FDA) approval process for new ingredients, including a growing class of compounds known as peptides. Industry groups are arguing the current system is hindering innovation and limiting consumer access to potentially beneficial products, while the FDA maintains its priority is public safety and rigorous testing remains crucial.

The core of the debate revolves around the 'New Dietary Ingredient Notification' (NDIN) process. Currently, any company wishing to add a novel ingredient to a dietary supplement must submit a detailed notification to the FDA, demonstrating its safety through extensive testing. This process can be lengthy - often taking years - and expensive, creating a significant barrier to entry for smaller companies and slowing the introduction of new products to market.

Industry advocates, such as the Council for Responsible Nutrition (CRN), propose a shift towards a 'risk-based framework.' Julie Mann, Senior Vice President of Scientific and Regulatory Affairs at the CRN, argues the existing process isn't geared towards efficiently evaluating the risks associated with new ingredients. "It's a barrier to innovation," she stated recently. "It prevents consumers from accessing ingredients that could be beneficial." The CRN suggests that ingredients with a demonstrably low risk profile, based on established scientific principles or historical use, should be allowed onto the market with a streamlined approval process. They envision a tiered system where higher-risk ingredients undergo more stringent testing, while lower-risk ingredients require less oversight.

Peptides, short chains of amino acids, are at the forefront of this push. These compounds are increasingly popular in the wellness space, touted for potential benefits ranging from muscle recovery and improved skin health to cognitive enhancement and weight management. However, the NDIN process treats each unique peptide as a completely novel substance, even if it's structurally similar to naturally occurring peptides already present in the human body. Manufacturers argue this is an overly cautious approach that fails to recognize the generally recognized safety of amino acid building blocks.

Former FDA Commissioner Scott Gottlieb, while acknowledging the industry's concerns, firmly defends the agency's position. "The agency's role is to ensure that consumers are safe," he explained in a recent interview. "And that includes evaluating the safety of these new ingredients." Gottlieb emphasizes that dietary supplements, unlike pharmaceutical drugs, are not subject to the same level of pre-market scrutiny. "Supplements don't undergo the same rigorous clinical trials as drugs. The FDA's role is to act as a critical safeguard, ensuring that what's being sold to consumers isn't harmful."

The argument highlights a fundamental difference in regulatory philosophy. Supplement manufacturers contend the FDA is applying a pharmaceutical standard to products intended for general wellness, rather than acknowledging the different risk profile associated with dietary supplements. They point to the widespread use of vitamins and minerals as examples of ingredients that were not subjected to the same exhaustive testing requirements before being made available to the public.

Legal expert Marc Ullman, a partner at Rivkin Radler specializing in FDA compliance, suggests a middle ground is possible. "What we're looking for is a more risk-based framework," he explained. "One that acknowledges the potential benefits of innovation while still protecting consumers from harm. The key is to develop clear criteria for assessing risk and tailoring the approval process accordingly."

The FDA is currently reviewing proposed changes to its dietary supplement regulations, taking into consideration the feedback from industry groups and consumer advocates. A final decision is anticipated in the coming weeks, and is likely to have significant implications for the future of the $50+ billion dietary supplement industry. Experts predict the decision will set a precedent for how the FDA approaches the regulation of other emerging classes of ingredients, including novel cannabinoids and synthetic biological compounds. The outcome will undoubtedly be scrutinized by both manufacturers eager to innovate and consumer groups determined to ensure the safety and efficacy of the products they consume. The debate underscores the ongoing tension between fostering innovation and safeguarding public health in a rapidly evolving market.